Updates in Cardiovascular Risk Reduction in Type 2 Diabetes: New Insights and Outcomes in Treatment Options

Sunday, April 3, 2016 | 6:30 – 9:30 PM EST
Westin Boston Waterfront Hotel, Grand Ballroom

This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.

This activity is supported by an educational grant from Boehringer Ingelheim and Lilly USA, LLC.

SYMPOSIUM AGENDA

Opening and Welcome
Program Director: Benard Zinman, MD – University of Toronto (Canada)

Cardiovascular Risk Screening and Prevention: Who, When, How Often, What Medication?
Naveed Sattar, MD, PhD – University of Glasgow

Cardiovascular Effects of Medications for Glycemic Control: Evidence from Large Outcomes Trials
Hertzel Gerstein, MD – McMaster University (Canada)

SGLT-2 Inhibitors: Cardiovascular Impact and Safety Concerns
Silvio Inzucchi, MD – Yale University

Moderated Panel Discussion and Audience Questions 

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Summarize the most recent guideline recommendations for screening for coronary artery disease in T2D including specific goals in reducing risk factors and appropriate biochemical targets
  • Evaluate the benefits of statin therapy in patients to reduce CV risk taking into consideration recently described associations with new onset T2D
  • Describe the cardiovascular safety of new medications for glycemic control
  • Describe the mechanism of action of SGLT-2 inhibitors on kidney, liver, and vascular systems
  • Understand the efficacy and safety results of the EMPA-REG Outcome trial and the questions it raises about the potential benefits and risks of empagliflozin and other SGLT-2 inhibitors in people with T2DM, with or without CVD

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits™
  • 2.50 CME Certificate of Participation
Course opens: 
03/25/2016
Course expires: 
04/03/2017
Rating: 
5
Boston, MA 02210
United States

Bernard Zinman CM, MD, FRCPC, FACP – Program Director
Director, Leadership Sinai Centre for Diabetes
Sam and Judy Pencer Family Chair in Diabetes Research
Senior Scientist, Lunenfeld-Tanenbaum Research Institute
Professor of Medicine, University of Toronto
Toronto, Ontario, Canada

Naveed Sattar, MD, PhD
Professor of Metabolic Medicine
University of Glasgow
Glasgow, Scotland

Hertzel C. Gerstein, MD, MSc, FRCPC
Professor and Population Health Institute Chair in Diabetes Research
McMaster University and Hamilton Health Sciences
Hamilton, Ontario, Canada

Silvio E. Inzucchi, MD
Professor of Medicine
Clinical Director, Section of Endocrinology
Medical Director, Yale Diabetes Center
Yale School of Medicine
New Haven, Connecticut

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Hertzel Gerstein, MD: Consultant, Amgen, Boehringer Ingelheim, Kaneq Bioscience; Consultant and Research Support, Lilly, Merck; Consultant, Research Grant & Speaker, AstraZeneca, Sanofi; Consultant and Speaker, Abbott, Novo Nordisk; Speaker, Berline Chemie
Silvio Inzucchi, MD: Advisory Board Member, Janssen Pharmaceuticals, Merck & Co.; Coinvestigator, Takeda; Committee Member, Daiichi Sankyo, Novo Nordisk; Consultant, AstraZeneca, Sanofi
Bernard Zinman, MD: Chairman (Research Grants), AstraZeneca, Boehringer Ingelheim, Novo Nordisk

The following faculty reported no relevant financial relationships:  Naveed Sattar, MD, PhD

The following SPC member who reviewed content for this activity reported no relevant financial relationships: Connie B. Newman, MD

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits™
  • 2.50 CME Certificate of Participation